Why Automated Sampling Has Become a Strategic Decision
The bioprocess automation market is projected to reach $7.2 billion in 2026, growing at a 12.6% CAGR, with bioprocess analyzers and sampling technologies representing a $2.4 billion sub-segment growing at 10.1% annually. Behind these numbers sits a practical reality: every bioprocess lab running parallel bioreactors faces the same bottleneck.
Manual sampling from even a modest 8-bioreactor setup consumes 80–120 hours of technician time per 14-day fed-batch campaign. That figure includes nights, weekends, and the cognitive load of maintaining aseptic technique at 3 a.m. on a Saturday. When a technician's hands touch a sampling port, they introduce both a contamination vector and a source of variability. Cross-contamination between parallel reactors in a Design of Experiments study can invalidate weeks of work. Inconsistent sample volumes distort metabolite profiles. And gaps in sampling — the 6-hour window between scheduled manual draws — hide the very process excursions that engineers need to understand.
Automated sampling systems solve these problems, but they solve them differently. The market in 2026 offers a range of approaches: from established incumbents with deep ecosystem integration to newer entrants rethinking the architecture. This analysis examines the major solutions available today, evaluates their respective strengths and trade-offs, and models the total cost of ownership for realistic laboratory scenarios.
The goal is transparency. Every system discussed here has legitimate applications where it excels. The question for any lab is which combination of capabilities, constraints, and economics best fits their specific situation.
Sterile Sampling vs. Aseptic Sampling: A Critical Distinction
Before comparing platforms, it is worth clarifying a distinction that marketing materials often blur: sterile sampling and aseptic sampling are not the same thing.
What's the Difference?
Sterile Sampling
The baseline expectation for any automated bioreactor sampling system. It means the fluid path, connectors, and sample containers are free of viable microorganisms at the point of use. Most systems achieve this through autoclaving, chemical sterilization, or single-use sterile disposables. Sterile sampling prevents microbial contamination from the sampling system itself.
Aseptic Sampling
Goes further. It encompasses the entire workflow discipline — not just sterile components, but validated procedures for maintaining sterility throughout the sampling event, including connection and disconnection of fluid paths, operator technique, environmental controls, and documented standard operating procedures (SOPs). Aseptic sampling is what regulators mean when they reference GMP-compliant sampling: a validated, repeatable process with traceability from the bioreactor to the sample container.
In practice, this means an aseptic sampling capability requires more than sterile hardware. It requires a dedicated aseptic consumable set — pre-sterilized, validated, lot-traceable tubing, connectors, seals, and vials packaged as a single-use kit — paired with a documented SOP that defines each step of the sampling event, from pre-connection verification through sample labeling and storage. Without both elements, a system provides sterile sampling (clean components) but not aseptic sampling (validated process assurance).
The Competitive Landscape: Who Builds What
Eppendorf Bioprocess Autosampler
Robotic needle-based sampling with septum-sealed ports. A robotic arm moves a syringe-equipped tool to each bioreactor sampling port, pierces the septum, aspirates, then deposits the sample into septum-capped vials.
Eppendorf has the deepest integration within its own bioreactor ecosystem. The Bioprocess Autosampler connects seamlessly with DASbox (up to 16 mini bioreactors), DASGIP (up to 16 parallel vessels), SciVario twin (up to 8), and BioFlo 320 (up to 4). Software control lives inside DASware control 6, meaning a single interface manages bioreactors and sampling simultaneously. Sterile airflow around each needle tip provides contamination protection. Eppendorf has published extensive application data, including a May 2025 study demonstrating monoclonal antibody stability across extended automated sampling campaigns. The system provides sterile sampling as standard.
The system is designed exclusively for Eppendorf bioreactors. Labs running mixed-vendor equipment — which is the norm in many process development environments — cannot use the Eppendorf autosampler for their Sartorius, INFORS HT, or Applikon vessels. The septum-piercing mechanism places a physical limit on total sampling events per port before septum integrity degrades. Aseptic sampling with validated SOPs and dedicated consumable kits would need to be defined by the end user. The system's footprint is not designed for operation inside a Biosafety Cabinet (BSC).
DASware control 6 software is required and carries an annual license fee (estimated €5,000–€10,000/year). This is a subscription model — if the license lapses, software features may become restricted. The licensing cost is incremental to the hardware investment and compounds significantly over a 5-year ownership period.
Labs fully committed to the Eppendorf bioreactor ecosystem, particularly those running DASbox or DASGIP for high-throughput process development within a single vendor's hardware.
€50,000–€120,000 depending on configuration and bioreactor count, plus annual software licensing.
Securecell Numera
Modular flow-based sampling with integrated dilution, filtration, and analyzer routing. The system consists of a Control Module, Routing Module, and stackable Multiplexer Modules, with optional Dilution and Filtration Modules for in-line sample preparation.
Numera is arguably the most sophisticated sample preparation system on the market. Its tape-filtration technology provides cell-free samples for biochemical analyzers without centrifugation, and the integrated dilution module achieves precision ≤2% SD at ratios up to 1:20. Up to four Multiplexer Modules can be stacked, connecting 16 bioreactors to multiple analyzers simultaneously. Combined with Securecell's Lucullus SCADA software, it becomes a comprehensive bioprocess data platform. Securecell has also launched the Integra1-64 for true high-throughput applications at production scale. The platform provides sterile sampling through its closed fluid-path design.
The system's strength — integrated sample preparation — also defines its complexity. The multi-module architecture (Control + Routing + Multiplexers + optional Dilution + optional Filtration) means a significant footprint and a steeper learning curve for installation and maintenance. Numera is primarily oriented toward online analyzer feeding rather than standalone vial-based sample archival. The multi-module footprint makes BSC placement impractical. Pricing reflects the sophistication: complete systems with all modules represent a substantial capital investment.
Lucullus SCADA software carries an annual license fee (estimated €8,000–€16,000/year depending on module count and feature tier). Lucullus is central to the system's value proposition — it provides SCADA, data management, and process control. The recurring cost is significant but delivers genuine ongoing value through software updates and expanded analytics. However, for labs that only need basic sampling without advanced SCADA, the license represents overhead.
Mid-to-large-scale bioprocess development labs and CDMOs that need tight integration between sampling and online analytics (HPLC, cell counters, metabolite analyzers), and have the budget and technical staff to fully leverage the platform.
€80,000–€200,000 depending on module configuration, plus annual Lucullus licensing.
Flownamics Seg-Flow S3 and Seg-Flow PS
Segmented-flow sampling using air-liquid segmentation to transport samples through shared tubing to analyzers or fraction collectors. The patented approach uses air plugs to isolate each sample segment, reducing cross-contamination in shared fluid paths.
Flownamics' segmented-flow approach is elegant in its simplicity. By using air as a physical barrier between sample segments, the system achieves low carryover without requiring dedicated tubing per bioreactor. The Seg-Flow S3 supports 8 vessels with delivery to up to 4 analyzers simultaneously, with optional Sample-Mod S3 for in-line dilutions (up to 1:20). The Seg-Flow PS targets cell and gene therapy applications with a compact, modular design that sits near the bioreactor. FlowWeb software provides OPC-compatible data export to SCADA systems. A strategic partnership with Beckman Coulter integrates the Vi-CELL BLU cell counter for automated cell viability analysis. Sterile sampling is achieved through the closed segmented-flow architecture.
The Seg-Flow platform is primarily an online sampling system — it excels at feeding analyzers but does not emphasize temperature-controlled vial archival in the way Eppendorf does. The 8-vessel limit per system is adequate for many labs but constraining for high-throughput screening. While the segmented-flow approach reduces carryover effectively, labs running GMP processes or contamination-sensitive cell cultures may prefer truly dedicated fluid paths. The system is not designed for BSC-internal operation.
FlowWeb software is typically included with the hardware purchase or carries a modest one-time license fee. This is one of Flownamics' competitive advantages — lower ongoing software costs compared to subscription-based competitors. Some advanced features or updates may require service agreements, but the base software model is more favorable for long-term TCO.
Labs focused on continuous online monitoring with at-line analyzers, particularly those already using or planning to use Beckman Coulter Vi-CELL BLU. Also suitable for PAT (Process Analytical Technology) implementations where real-time analyzer data is the primary objective.
€40,000–€100,000 depending on model and analyzer integration, with FlowWeb software typically included.
Merck MAST (Modular Automated Sampling Technology)
Modular automated aseptic sampling designed for GMP-ready environments. Originally developed by Lonza and acquired by Merck in 2022, the MAST platform uses Sample Pilot modules — the SP100 for stainless-steel bioreactors (SIP-compatible) and SP200 for single-use and development-scale vessels.
MAST carries the strongest regulatory pedigree. Built for pharmaceutical manufacturing environments from the ground up, it addresses GMP requirements natively — including aseptic sampling with validated processes. The system connects up to 10 bioreactors to four primary analyzers per unit. Its modality-agnostic design handles upstream processing, downstream processing, and microbial fermentation alike. Merck's acquisition brought the platform into a broader portfolio that includes process development tools, filtration, and chromatography — creating potential for integrated workflow solutions. The SP200's compatibility with single-use technology aligns with the market's single-use momentum (44.9% of the bioprocess automation market, growing at 16% CAGR).
MAST is built for manufacturing-scale thinking. This translates to higher complexity and cost compared to benchtop-focused alternatives. The 10-bioreactor limit per unit is lower than competitors. The system's footprint is designed for manufacturing suites, not benchtop or BSC environments. The system is optimized for the pharmaceutical GMP context, which means labs in early-stage R&D or academic settings may be paying for regulatory infrastructure they do not yet need. Pricing is at the premium end of the market, reflecting the GMP-grade design and Merck's enterprise positioning.
MAST software and service agreements are enterprise-grade, with annual costs for software maintenance, support, and validation services. Pricing is typically bundled into service contracts that include on-site support, calibration, and software updates. The enterprise approach aligns with pharmaceutical procurement models but represents significant recurring cost. Exact annual fees are negotiated per installation.
Pharmaceutical manufacturing sites, late-stage process development, and GMP environments where regulatory compliance, single-use compatibility, and integration with Merck's broader bioprocessing portfolio are priorities.
€100,000–€300,000 depending on configuration, with additional annual service agreement costs.
Solaris LEDA
A sterile sampling probe system using needle-free connectors with autoclavable components. The LEDA is a compact, per-bioreactor sampling device rather than a centralized multi-bioreactor system.
LEDA provides up to 180 sterile samplings per batch at very low cost per bioreactor. The fully autoclavable design (121–133°C, 30 minutes) means no chemical sterilization between batches. Syringe options (3, 5, or 10 mL) provide volume flexibility. The needle-free connector eliminates septum degradation over repeated samplings. As a per-bioreactor accessory, it integrates naturally into Solaris Jupiter and Saturn bioreactor setups.
LEDA is a semi-automated sampling aid rather than a fully automated system. It does not provide scheduled, unattended sampling or analyzer integration. A technician still initiates each sampling event. It is limited to Solaris bioreactors. There is no software-controlled scheduling, adaptive sampling, or data logging beyond what the bioreactor controller provides. No BSC-compatible form factor.
No software license required. The LEDA is a hardware-only accessory with no recurring software costs. Replacement consumables (septa, connectors) are the only ongoing expense.
Solaris bioreactor users who want to improve sampling sterility and consistency without investing in a full automation platform. Suitable for labs where a technician is present during sampling but needs better aseptic technique assurance.
Typically under €5,000 per bioreactor — an order of magnitude less than centralized systems, but with proportionally reduced capability.
LAMBDA Omnicoll
A programmable fraction collector that can be coupled with a peristaltic pump for time-based or event-triggered automated sample collection from bioreactors.
The Omnicoll offers exceptional timing flexibility, with sampling intervals from 0.1 minutes to 166 hours. When paired with a multichannel peristaltic pump, it can sample from multiple bioreactors simultaneously. Event-triggered sampling based on fermentation alarm signals is supported. The system is vendor-agnostic — it works with any bioreactor that has a sample port. Cost-effective relative to the dedicated bioprocess autosampling platforms.
The Omnicoll is a general-purpose fraction collector adapted for bioprocess use, not a purpose-built aseptic sampling system. It lacks integrated cleaning protocols, aseptic barrier technology, and cross-contamination verification. The system does not provide the regulatory traceability (21 CFR Part 11, electronic audit trails) that pharmaceutical environments require. No direct analyzer integration. Not designed for BSC placement.
No recurring software fees. The system includes its control software with the hardware purchase. No ongoing license or subscription costs.
Academic and early-research labs that need basic timed sampling at low cost and are comfortable managing aseptic technique and sample storage independently. Also useful as a supplementary collection device in non-critical applications.
€3,000–€8,000 depending on configuration and pump selection.
BioSamplr (Open Source)
A 3D-printed, Raspberry Pi-controlled automated sampling device that moves a needle through a Cartesian system to collect up to 10 samples into chilled microcentrifuge tubes.
At approximately $700 in materials, BioSamplr is by far the lowest-cost entry point into automated sampling. Its open-source design (hardware and software) allows complete customization. The Raspberry Pi controller enables wireless operation and automated data logging. Published in HardwareX (2021) with validated performance data.
BioSamplr is an academic proof-of-concept, not a commercial product. The 10-sample capacity limits its utility for extended campaigns. There is no aseptic barrier technology, no cleaning validation, no GMP compliance pathway, and no commercial support. Assembly requires 3D printing capability and technical competence with Raspberry Pi. Not suitable for any regulated environment.
Fully open source. No license costs of any kind. Community-supported only.
Academic research labs with strong DIY culture, budget constraints, and non-regulated experimental contexts where 10 samples per run are sufficient.
~$700 in components (self-assembled).
QB AutoSampler by QB Systems
A modular, benchtop automated sampling platform designed around software-configurable fluid paths, modular hardware expansion, and vendor-agnostic bioreactor connectivity. The base unit connects 4 bioreactor sources, with tool-free expansion modules adding 4 sources each up to a maximum of 24. All hardware modifications — expansion, reconfiguration, adapter changes — are designed to be performed by lab personnel without requiring automation specialists or vendor service visits.
The QB AutoSampler addresses several gaps that exist between the incumbents. Its three configurable path modes — Dedicated (one path per bioreactor, zero shared surfaces), Shared (one path with 5-stage automated cleaning), and Hybrid (clustered groups combining both approaches) — let a single system serve different contamination strategies without hardware changes. The 24-source maximum exceeds every current competitor by at least 50%. Its vendor-agnostic design supports Eppendorf, Sartorius, INFORS HT, Solaris, Applikon, generic glass (PG13.5), and single-use bags through an adapter kit — directly targeting the mixed-vendor labs that cannot use the Eppendorf system.
BSC-compatible footprint — a unique capability. One of the most significant and often overlooked constraints in automated sampling is physical form factor. Cell and gene therapy manufacturing frequently operates inside Class II Biosafety Cabinets, where the working area is typically 1.2 m wide × 0.6 m deep. No currently available commercial automated sampling system is designed to operate within this envelope. The QB AutoSampler's base footprint of ≤0.15 m² (roughly 40 cm × 38 cm) is specifically engineered for BSC-internal placement, leaving sufficient workspace for bioreactor vessels, tubing connections, and operator access. This is not merely a size advantage — it is a capability that no other system on the market can claim. For cell therapy labs where all manipulations must occur inside a BSC, the alternative to a BSC-compatible sampler is manual sampling through the BSC opening, which is precisely the contamination bottleneck that automation is meant to eliminate.
Sterile and aseptic sampling. The QB AutoSampler provides sterile sampling as its baseline — all wetted components are validated for sterility, and the 5-stage cleaning protocol (air purge, primary wash, secondary rinse, air dry, optional disinfection hold) with optional in-line carryover verification (UV/Vis or conductivity sensor) ensures path cleanliness between samples. Beyond this baseline, QB Systems offers a dedicated Aseptic Consumable Set — a pre-sterilized, lot-traceable kit of tubing, connectors, seals, and vials — paired with a validated Aseptic Sampling SOP that defines each step from pre-connection verification through sample labeling and chain-of-custody documentation. This two-tier approach (sterile baseline + aseptic upgrade) allows labs to match their investment to their regulatory requirements: R&D labs can operate with standard sterile sampling, while GMP-aware and cell therapy environments can deploy the full aseptic workflow with audit-ready documentation.
QB Systems' adaptive sampling — reading real-time process data via OPC-UA or Modbus and automatically adjusting sampling frequency — goes beyond the fixed and variable-interval scheduling common across the market. When glucose consumption rate accelerates during exponential growth, the sampler tightens its interval from 4 hours to 30 minutes without operator action.
The pricing model is equally distinctive: €15,000 for the base system with all core software included under a perpetual license. Standard (non-aseptic) consumables use non-proprietary components at ≤€500 per 1,000 samples. Aseptic consumable kits — pre-sterilized, lot-traceable, and SOP-paired — are available separately at higher cost reflecting the additional validation and traceability requirements.
QB Systems is a newer entrant in the dedicated bioprocess autosampling segment. While the company has an established track record in modular liquid handling, the AutoSampler does not yet carry the years of published peer-reviewed application data that Eppendorf, Securecell, and Flownamics have accumulated. Labs in validated GMP production environments may require additional time for the platform to build the same depth of regulatory reference installations. The 5-stage cleaning protocol with optional carryover verification is technically comprehensive, but shared-path configurations always carry some inherent complexity compared to single-use disposable approaches.
QB Control software is provided under a perpetual license — the license never expires, and all features purchased remain available indefinitely regardless of support contract status. Annual support is available in tiered levels and covers software updates, technical support response times, and access to new feature releases. This model is fundamentally different from the subscription licensing used by Eppendorf (DASware), Securecell (Lucullus), and Merck (MAST service contracts), where software access is contingent on maintaining an active subscription. With the QB model, if a lab chooses not to renew support in a given year, the system continues to operate with full functionality — it simply does not receive updates or priority technical assistance during that period. Support can be re-activated at any time.
The QB AutoSampler supports the following 21 CFR Part 11 requirements: immutable audit trail with timestamped logging of all system events, role-based access control (Scientist, QA Manager, Administrator, Service), data integrity through encrypted storage and backup, and automated batch report generation (CSV, JSON, PDF). Note: Electronic signatures are not currently supported by the QB AutoSampler platform. Labs requiring electronic signature functionality for 21 CFR Part 11 compliance should implement this through their LIMS or quality management system, which is a common industry practice for distributed instrumentation.
Process development labs with mixed-vendor bioreactor fleets, labs scaling from small to large parallel configurations, cell therapy operations requiring BSC-internal automation, and organizations that want a single platform serving R&D through GMP-ready workflows. Particularly compelling for startups and CDMOs where TCO sensitivity is high and vendor lock-in is strategically unacceptable.
From €15,000 base (4 sources), scaling through tool-free expansion modules. Perpetual software license included. Optional annual support tiers available.
Feature Comparison Matrix
| Capability | Eppendorf | Securecell Numera | Flownamics Seg-Flow | Merck MAST | QB AutoSampler |
|---|---|---|---|---|---|
| Max Sources | 16 | 16 | 8 | 10 | 24 |
| Path Architecture | Serial/Clustered | Shared | Shared (segmented flow) | Shared | Dedicated + Shared + Hybrid |
| Adaptive Sampling | No | No | No | No | Yes (OPC-UA/Modbus) |
| Vendor-Agnostic | Eppendorf only | Partial | Broad | Partial | All major vendors |
| BSC Compatible | No | No | No | No | Yes (≤0.15 m²) |
| Aseptic Consumable Kit + SOP | User-defined | User-defined | User-defined | Included (GMP) | Available (dedicated kit + SOP) |
| Online Analyzers | No | Up to 4+ | Up to 4 | Up to 4 | Up to 6 |
| Cleaning Protocol | Ethanol sanitation | Multi-stage | Air segmentation | GMP-grade | 5-stage + optional verification |
| 21 CFR Part 11 | Via DASware | Via Lucullus | No | Yes (full) | Partial (no e-signatures) |
| Software License Model | Annual subscription | Annual subscription | Included/modest | Enterprise contract | Perpetual (support optional) |
| Bolus Addition | Yes (tied to sampling) | No | No | No | Yes (independent) |
| Starting Price | ~€50K | ~€80K | ~€40K | ~€100K | €15K |
Note: Specifications based on publicly available data as of early 2026. Contact vendors for current configurations and pricing.
Software Licensing Models: A Deeper Comparison
Software costs are frequently underestimated in capital equipment decisions. Over a 5-year ownership period, recurring license fees can exceed the original hardware investment. Understanding each vendor's model is essential for accurate TCO planning.
| Vendor | License Type | Estimated Annual Cost | 5-Year Software Cost | What Happens If You Stop Paying |
|---|---|---|---|---|
| Eppendorf (DASware) | Annual subscription | €5,000–€10,000 | €25,000–€50,000 | Reduced functionality; sampling may require manual control |
| Securecell (Lucullus) | Annual subscription | €8,000–€16,000 | €40,000–€80,000 | SCADA and analytics features restricted; basic operation may continue |
| Flownamics (FlowWeb) | Included / modest fee | €0–€2,000 | €0–€10,000 | Full functionality retained; updates may cease |
| Merck MAST | Enterprise service contract | €10,000–€20,000 | €50,000–€100,000 | Service, validation, and updates cease; software may continue at last version |
| QB Systems (QB Control) | Perpetual license | Support tiers optional | Support cost only | Full functionality retained indefinitely; updates and priority support paused |
Note: Specifications based on publicly available data as of early 2026. Contact vendors for current configurations and pricing.
The difference is structural. Subscription models (Eppendorf, Securecell, Merck) treat software as an ongoing service — the vendor maintains access, and the customer pays continuously for that access. This model aligns vendor and customer incentives around ongoing value delivery, but it creates a recurring cost obligation that compounds over time. For a 16-bioreactor Numera installation, 5 years of Lucullus licensing alone can reach €80,000 — more than the starting price of several competing hardware platforms.
Perpetual license models (QB Systems, Flownamics) treat software as a one-time purchase. The customer owns the license permanently. Optional support contracts provide updates and technical assistance, but the core software remains fully functional regardless. This model favors labs that want predictable long-term costs and resist ongoing vendor dependencies.
Neither model is inherently superior. Subscription models deliver continuous updates and support; perpetual models deliver cost certainty and independence. The right choice depends on whether a lab values ongoing vendor engagement or long-term cost control.
Total Cost of Ownership: Three Scenarios
Cost decisions in lab automation are rarely about the purchase price alone. Software licenses, consumables, integration labor, and expansion costs compound over a system's useful life. The following models use publicly available pricing estimates and reasonable assumptions to illustrate how total cost of ownership diverges across platforms over five years.
Assumptions Common to All Scenarios
- Campaign duration: 14-day fed-batch, 6-hourly sampling = ~56 samples/bioreactor/campaign
- Campaigns per year: 12 (average for an active PD lab)
- Technician fully loaded cost: €45/hour
- Manual sampling time per round: 20 minutes per bioreactor
- Annual software license estimates based on publicly available information and industry benchmarks
- QB Systems annual support estimated at entry-level tier for TCO calculations
- Consumable costs based on published or estimated per-sample rates
- All figures are estimates intended for comparative illustration; actual pricing should be confirmed with vendors
Scenario 1: Early-Stage Biotech Startup
Lab profile: 4 benchtop bioreactors (mixed vendors: 2× Eppendorf DASbox, 1× Sartorius, 1× glass flask), 2 scientists, no LIMS, limited budget.
| Cost Element (5 Years) | Manual Sampling | Eppendorf | Flownamics | QB AutoSampler |
|---|---|---|---|---|
| Capital | €0 | N/A* | €45,000 | €15,000 |
| Software licenses (5 yr) | €0 | N/A* | €0 | €0 (perpetual) |
| Annual support (5 yr) | €0 | N/A* | €0–€5,000 | €5,000 (est.) |
| Consumables (5 yr) | €2,000 | N/A* | €10,000 | €6,700 |
| Labor: sampling (5 yr) | €100,800 | N/A* | €5,000 | €5,000 |
| Integration/installation | €0 | N/A* | €3,000 | €2,000 |
| 5-Year Total | €102,800 | N/A* | €63,000–€68,000 | €33,700 |
*Eppendorf cannot serve this lab — 2 of 4 bioreactors are non-Eppendorf brands.
ROI Analysis for QB AutoSampler
- Annual labor savings: (4 bioreactors × 56 samples × 20 min × 12 campaigns) / 60 min × €45 = €20,160/year
- Net annual benefit (after consumables and support): ~€18,480/year
- Payback period: €22,000 total initial investment ÷ €18,480/year = ~1.2 years (14 months)
- 5-year ROI: (€69,100 net savings) ÷ €22,000 investment = 314%
Scenario 2: CDMO Process Development Lab — 16 Bioreactors
Lab profile: 16 parallel bioreactors for DoE (mixed vendors), HPLC and cell counter online, LabWare LIMS, GMP-aware workflows, 5 scientists. Requires aseptic sampling with validated SOPs.
| Cost Element (5 Years) | Manual Sampling | Eppendorf | Securecell Numera | QB AutoSampler |
|---|---|---|---|---|
| Capital | €0 | N/A* | €160,000 | €55,000 |
| Software licenses (5 yr) | €0 | N/A* | €60,000 | €0 (perpetual) |
| Annual support (5 yr) | €0 | N/A* | incl. in license | €10,000 (est.) |
| Aseptic consumable kits (5 yr) | €4,000 | N/A* | €15,000 | €13,400 |
| Standard consumables (5 yr) | €4,000 | N/A* | €15,000 | €13,400 |
| Labor: sampling (5 yr) | €403,200 | N/A* | €15,000 | €15,000 |
| LIMS integration | €0 | N/A* | €15,000 | €5,000 |
| Maintenance (5 yr) | €0 | N/A* | €25,000 | €10,000 |
| 5-Year Total | €411,200 | N/A* | €305,000 | €121,800 |
*Eppendorf cannot serve mixed-vendor bioreactors. If all 16 were Eppendorf: estimated 5-year total ~€175,000–€225,000 including software licenses.
ROI Analysis for QB AutoSampler
- Annual labor savings: (16 bioreactors × 56 samples × 20 min × 12 campaigns) / 60 min × €45 = €80,640/year
- Additional value: reduced contamination risk in DoE (estimated 2 invalid campaigns avoided per year × €15,000 = €30,000/year)
- Net annual benefit: ~€105,640/year
- Total 5-year investment: €121,800
- Payback period: ~0.9 years (11 months)
- 5-year ROI: (€289,400 net savings vs. manual) ÷ €121,800 = 238%
- Savings vs. Numera: €305,000 − €121,800 = €183,200
Scenario 3: Scaling Growth — From 4 to 24 Sources Over 3 Years
Lab profile: Starting with 4 bioreactors, expanding to 12 in Year 2 and 24 in Year 3. This scenario tests how modular versus monolithic architectures handle growth — focusing on what is operationally required at each stage rather than incremental pricing.
The core question: When your lab grows, can your sampling system grow with it — without requiring automation specialists, system replacements, or extended downtime?
| Growth Stage | Eppendorf | Securecell Numera | Flownamics Seg-Flow | QB AutoSampler |
|---|---|---|---|---|
| Year 1: 4 sources | Base system installation. Requires Eppendorf bioreactors only. | Base + 1 Multiplexer Module. Requires specialist installation for Control + Routing + Multiplexer modules. | Base S3 unit. Supports up to 8 vessels. | Base unit. Any vendor bioreactors. Lab staff install using adapter kit. |
| Year 2: Expand to 12 | Second autosampler unit required (max 16 per unit but reconfiguration needed). Vendor service visit for installation. Additional DASware license. | Additional Multiplexer Modules. Vendor or trained specialist required for module stacking and routing reconfiguration. Additional Lucullus license capacity. | Second S3 unit required (max 8 per unit). Separate software instance. | Tool-free hardware + simple software update: Lab staff click in 2 expansion modules (4 sources each), then modify the process definition in QB Control and redeploy the updated configuration to include the new hardware. No vendor visit. No recalibration. All steps performed by the lab operator — no automation specialist required. Under 30 minutes total. |
| Year 3: Expand to 24 | Cannot reach 24. Maximum 16 per system. Third unit or entirely different platform needed. | Cannot reach 24. Maximum 16 per system. Integra1-64 is a different product class entirely. | Cannot reach 24. Maximum 8 per unit; third unit required for 24 with three separate systems to manage. | Tool-free hardware + simple software update: Lab staff click in 3 additional expansion modules, update the process definition in QB Control, and redeploy. Same straightforward process as Year 2 — all performed by lab personnel. Total: 24 sources on one platform, one software instance, one bench footprint. |
| Software impact | Additional DASware licenses per unit. Multiple software instances to manage if multiple units. | Additional Lucullus license capacity. Single instance if within system limits. | Multiple FlowWeb instances for multiple units. | No change. Perpetual license covers all expansion modules automatically. No additional software cost at any stage. |
| Expert required? | Yes — vendor service for reconfiguration | Yes — specialist for module stacking | Yes — for each additional unit setup | No — all expansions by lab personnel |
| Downtime during expansion | Hours to days (second system install) | Hours (module restacking, reconfiguration) | Hours (second unit setup) | Under 30 minutes (tool-free module click-in + process definition update and redeployment in QB Control) |
ROI Beyond Labor: The Hidden Value Drivers
The TCO models above capture direct costs, but three additional value drivers deserve consideration:
1. Data Density and Process Understanding
Adaptive sampling — which only the QB AutoSampler currently offers — captures process excursions that fixed-interval systems miss. When a glucose excursion triggers automatic 15-minute sampling instead of 4-hour intervals, the resulting dataset contains 16× more data points during the critical event. Over a year's campaign cycle, this translates into faster process characterization, fewer failed scale-up transfers, and shorter time-to-IND for biologics developers.
2. Contamination Cost Avoidance
In DoE campaigns running 16 parallel conditions, a single cross-contamination event can invalidate 4–8 conditions, wasting €15,000–€40,000 in media, analyst time, and schedule delay. The QB AutoSampler's dedicated path mode eliminates this risk category entirely. Shared-path systems mitigate it through cleaning validation, but dedicated paths provide deterministic assurance that no shared surface exists.
3. Vendor Flexibility as Strategic Optionality
Labs locked to a single bioreactor vendor pay an implicit premium in reduced negotiating leverage. A vendor-agnostic sampling system preserves the freedom to adopt the best bioreactor for each application — Eppendorf DASbox for small-volume screening, Sartorius ambr for scale-down models, single-use bags for clinical material — without the sampling system dictating the reactor choice.
Making the Decision: A Framework
No single system is optimal for every lab. The right choice depends on three questions:
1. What is your bioreactor ecosystem — and does your sampler fit where it needs to operate?
If you run exclusively Eppendorf bioreactors on open benchtops, the Eppendorf Bioprocess Autosampler offers the tightest integration and simplest implementation. If you run mixed-vendor equipment, vendor-agnostic platforms (QB AutoSampler, Flownamics) eliminate a structural constraint. And if you operate inside Biosafety Cabinets — as cell and gene therapy labs increasingly do — the QB AutoSampler's BSC-compatible footprint (≤0.15 m²) is currently the only automated option that fits inside the working envelope without compromising workspace.
2. What level of sampling assurance does your application require?
If sterile sampling is sufficient for your regulatory context, most platforms on the market meet this need. If you require validated aseptic sampling with dedicated consumable kits, documented SOPs, and lot traceability, confirm that your chosen platform offers this as a defined product — not as a "bring your own SOP" exercise. The QB AutoSampler and Merck MAST both provide structured aseptic sampling pathways; other platforms may require end-user validation.
3. What is your growth trajectory — and who performs the expansion?
If your source count will remain stable, capital efficiency at today's scale matters most. If you anticipate significant growth, evaluate not just whether a system can scale, but how it scales: Does expansion require a vendor service visit or automation specialist? Does it demand a second system with separate software? Or can lab personnel perform the expansion in minutes without interrupting running experiments? The answer to these questions determines whether growth is a budget event or a Tuesday afternoon task.
Conclusion
The benchtop automated sampling market in 2026 is more capable and more diverse than at any point in its history. Eppendorf brings ecosystem depth. Securecell brings analytical sophistication. Flownamics brings elegant simplicity. Merck MAST brings GMP pedigree. QB Systems brings architectural flexibility, BSC-compatible form factor, and aggressive economics.
For labs entering the automated sampling decision for the first time — particularly those with mixed-vendor bioreactors, growth ambitions, BSC operational requirements, or sensitivity to total cost of ownership — the QB AutoSampler represents a meaningful shift in the price-to-capability ratio. Its combination of 24-source scalability, configurable path architecture, BSC-compatible footprint, aseptic sampling with dedicated consumable kits, adaptive sampling intelligence, and a perpetual licensing model starting at €15,000 creates a value proposition that the established players have not yet matched.
But capability is not the same as universal superiority. The right system is the one that fits your bioreactors, your workflows, your regulatory requirements, your growth plan, and your budget. The data in this analysis should help you ask the right questions of every vendor on your shortlist.
Disclaimer
Pricing estimates and competitor specifications in this article are based on publicly available information, industry benchmarks, and reasonable assumptions as of early 2026. Actual pricing, specifications, and availability should be confirmed directly with each vendor. QB Systems provided product specifications for the QB AutoSampler; all competitive data was independently sourced. The TCO and ROI calculations use assumed parameters and are intended as illustrative frameworks, not guarantees of specific outcomes.
QB AutoSampler 21 CFR Part 11 Support: Includes audit trail, role-based access control, data integrity, and automated batch reporting; electronic signatures are not currently supported and should be implemented through the customer's LIMS or quality management system.